文献速递白血病

KDM6A缺失赋予急性髓系白血病耐药性

Loss of KDM6A confers drug resistance in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-06-14

该研究报道组蛋白H3K27去甲基化酶KDM6A(UTX)在复发AML中受失活突变及突变非依赖调控影响。配对诊断与复发标本显示复发时KDM6A突变肿瘤群体扩增,45.7%的CN-AML患者观察到复发特异性KDM6A表达缺失。KDM6A缺失的髓系白血病细胞对阿糖胞苷(AraC)和柔红霉素更耐药,机制为ENT1(SLC29A1)启动子H3K27乙酰化降低导致其下调。

要点

  • 复发AML中KDM6A受失活突变及突变非依赖调控影响。
  • 45.7%的CN-AML患者观察到复发特异性KDM6A表达缺失。
  • KDM6A缺失通过下调ENT1(SLC29A1) confer对AraC的耐药性。

核心结论

  • KDM6A缺失通过下调ENT1(SLC29A1)使髓系白血病细胞对AraC和柔红霉素更耐药。
  • KDM6A缺失在化疗期间赋予细胞选择性优势,导致复发时KDM6A突变或表达降低的克隆扩增。

研究设计与样本

  • 研究分析了配对诊断与复发标本中KDM6A突变及表达情况。
  • 使用KDM6A缺失的髓系白血病细胞系进行药物敏感性及功能研究。

主要发现

  • 配对诊断与复发标本显示复发时KDM6A突变肿瘤群体扩增。
  • 45.7%的CN-AML患者观察到复发特异性KDM6A表达缺失。
  • KDM6A缺失的髓系白血病细胞对AraC和柔红霉素治疗更耐药。
  • KDM6A缺失细胞系中诱导性重新表达KDM6A抑制增殖并重新增敏AraC治疗。
  • AraC耐药由ENT1(SLC29A1)启动子H3K27乙酰化降低导致ENT1下调所介导。

临床怎么用

  • 复发AML中可检测KDM6A突变及表达缺失。
  • KDM6A缺失状态可能与对AraC和柔红霉素的耐药相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or acquired drug resistance represents a major challenge. Here, we report that histone 3 lysine 27 demethylase KDM6A (UTX) is targeted by inactivating mutations and mutation-independent regulation in relapsed AML. Analyses of matched diagnosis and relapse specimens from individuals with KDM6A mutations showed an outgrowth of the KDM6A mutated tumor population at relapse. KDM6A expression is heterogeneously regulated and relapse-specific loss of KDM6A was observed in 45.7% of CN-AML patients. KDM6A-null myeloid leukemia cells were more resistant to treatment with the chemotherapeutic agents cytarabine (AraC) and daunorubicin. Inducible re-expression of KDM6A in KDM6A-null cell lines suppressed proliferation and sensitized cells again to AraC treatment. RNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus. Our results show that loss of KDM6A provides cells with a selective advantage during chemotherapy, which ultimately leads to the observed outgrowth of clones with KDM6A mutations or reduced KDM6A expression at relapse.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stief SM, Hanneforth AL, Weser S, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia. 2019. PMID: 31201358. doi:10.1038/s41375-019-0497-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。